

REMARKS

The Examiner required restriction to one of the following inventions under 35 U.S.C. 121:

- Group I: Claim 2, drawn to a method that provides treatment for sepsis.
- Group II: Claim 3, drawn to a method that provides treatment for inflammation.
- Group III: Claims 4, drawn to a method that provides treatment for infection.
- Group IV: Claim 15, drawn to a pharmaceutical composition for providing treatment for sepsis.
- Group V: Claim 16, drawn to a pharmaceutical composition for providing treatment for inflammation.
- Group VI: Claim 17, drawn to a pharmaceutical composition for providing treatment for infection.

The Examiner maintains that Claims 1 and 5-13 link Groups I-III above, and claims 14 and 18-26 link Groups IV-VI. Applicant hereby elects to prosecute the claims of Group II, claim 3 and linking claims 1, and 5-13, drawn to a method that provides treatment for inflammation. Applicant reserves the right to pursue one or more divisional applications directed to the nonelected claims.

The Examiner further requires election of a species as follows:

- Species (i): A molecule (a peptide, cholesterol absorption inhibitor, a viral fusion inhibitor, etc.) that targets SR-B1/CLA-1;
- Species (ii): An auxiliary agent or excipient or uptake facilitating agent; or
- Species (iii): Infection (viral, bacterial, etc.).

Applicant hereby elects to prosecute Species (i). As required by the Examiner, Applicant further elects the peptide species. Further, Applicant elects SEQ ID NO: 10.

This constitutes a request for any needed extension of time and an authorization to charge all fees therefor to deposit account No. 19-5117, if not otherwise specifically requested. The undersigned hereby authorizes the charge of any fees created by the filing of this document or any deficiency of fees submitted herewith to deposit account No. 19-5117.

Date: 7/5/2010

Respectfully submitted,

/Katherine Lobel-Rice/
Katherine Lobel-Rice #58,079
Swanson & Bratschun, L.L.C.
8210 Southpark Terrace
Littleton, CO 80120
Telephone: (303) 268-0066
Facsimile: (303) 268-0065

S:\ClientFolders\6137 (NIH)\6137NIDDK-2\PUS\Response to Restriction Requirement.doc